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Introduction: Clinical Translational Research and Rare Disease 
 
There are more than 6,000 unique and identifiable rare diseases that together affect 
millions of individuals. Underlying genetic etiology, information on surveillance, prognosis and 
tailored medical treatments are crucial for optimal survival and quality of life for these patients.  
Particularly when the genetic etiology of a disease is delineated, molecular pathways can be 
defined and this unlocks potential discovery for additional conditions and mechanisms.  Though 
tremendous progress has been made, we only have specific treatments for approximately 200 
rare disorders – and only a handful that could be considered an essential cure.   
While having a molecular diagnosis for a patient’s rare disease can mean everything to 
that family, it also holds high value to us in the scientific and medical communities.  
Understanding multi-faceted biochemical pathways is usually spearheaded by investigating a 
deficiency or an issue that causes a rare disease.  However, all patients, even with the same rare 
disease, are quite different.  They have their own genetic milieu as well as environmental factors 
that make their clinical story unique.   
The work of defining these rare diseases that are being discovered on a regular basis is 
imperative to support all, but especially levels T1, T2, and T3, of clinical translational research.   
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Without a solid understanding of what the molecular diagnosis is capable of, we cannot address 
the medical issues associated.   
The work included in this dissertation is limited to my three most important first author 
published manuscripts since starting the Clinical Translational Research (CTR) Mentored 
Scholar’s Program through the University of Nebraska Medical Center.   All are patient-inspired.  
During these past five years, I have also been involved with 16 additional manuscripts 
delineating the phenotype and care of rare disease.  Two in this dissertation are devoted to 
Myhre syndrome.  I was first introduced to Patient M while a fellow in medical genetics.  Now, 8 
years later, I am on the Myhre Professional Advisory Board and receive routine requests to 
provide medical opinions on this progressive condition.   The first article outlines 5 new patients 
with Myhre and was the first article defining the devastating cardiopulmonary issues that they 
can have.  It was recognized that this article could have such medical impact upon submission 
that the editors recommended publishing it urgently as a rapid communication and it was 
included in the AJMG Sequence publication as an article of high medical care impact.  The 
second article is the GeneReview for Myhre syndrome.  In rare disease it is well-known in the 
medical community that the go-to review for genetic diseases is the GeneReview.  It is an invited 
article and there is a rigorous editing process.  This article is by far the most impactful published 
work I have contributed to in my career.  The third manuscript, PIGQ 
Glycosylphosphatidylinositol-Anchored Protein (GPI-AP) Deficiency:  Characterizing the 
Phenotype, was published as a new syndrome article in the American Journal of Medical 
Genetics.  This is the first article describing this condition.  The editor, Dr. Max Muenke, included 
this article in his opening editorial of The Journal when referring to advances in identifying new 
genetic disorders.  
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Myhre Syndrome:  Clinical Features and Restrictive 
Cardiopulmonary Complications  
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Medicine, St. Louis, MO 
 3Children’s Hospital and Medical Center; Division of Cardiology; Omaha, Nebraska 
4Children’s Hospital and Medical Center; Division of Cardiac Surgery; Omaha, Nebraska 
5University of Nebraska Medical Center and the Munroe-Meyer Institute for Genetics and Rehabilitation; 
Human Genetics Laboratory; Omaha, Nebraska 
6Children’s Hospital and Medical Center; Division of Pediatric Pathology; Omaha, Nebraska 
7Arkansas Children’s Hospital; Division of Medical Genetics; Little Rock, Arkansas 
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ABSTRACT 
Myhre syndrome, a connective tissue disorder characterized by deafness, restricted 
joint movement, compact body habitus, and distinctive craniofacial and skeletal 
features, is caused by heterozygous mutations in SMAD4.  Cardiac manifestations 
reported to date have included patent ductus arteriosus, septal defects, aortic 
coarctation and pericarditis.  We present five previously unreported patients with 
Myhre syndrome.  Despite varied clinical phenotypes all had significant cardiac and/or 
pulmonary pathology and abnormal wound healing.  Included herein is the first report 
of cardiac transplantation in patients with Myhre syndrome.  A progressive and 
markedly abnormal fibroproliferative response to surgical intervention is a newly 
delineated complication that occurred in all patients and contributes to our 
understanding of the natural history of this disorder.  We recommend routine 
cardiopulmonary surveillance for patients with Myhre syndrome.  Surgical intervention 
should be approached with extreme caution and with as little invasion as possible as the 
propensity to develop fibrosis/scar tissue is dramatic and can cause significant morbidity 
and mortality.   
Key Words: Myhre syndrome; SMAD4; connective tissue disorder; restrictive 
cardiomyopathy; TGFβ 
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INTRODUCTION 
Over 30 years ago Myhre and colleagues described a syndrome characterized by 
deafness, dysmorphic facial features, thick or stiff skin, restrictive joint movement, 
skeletal anomalies, and short stature with muscular/thick-appearing or “compact” body 
habitus [Myhre et al., 1981].  Subsequent to the original publication, others have further 
defined the facial, skeletal, respiratory and upper airway features of the syndrome and 
have expanded the clinical phenotype to include variable neurodevelopmental features 
[Rulli et al., 2004; Lopez-Cardona et al., 2004; Titomanlio et al., 2001; Burglen et al., 
2003; Bachmann-Gagescu et al., 2011, McGowen et al., 2011].  In 2011, the genetic 
basis for Myhre syndrome was identified with documentation of mutations within a very 
restricted range of SMAD4 [Caputo et al., 2012; Le Goff et al., 2012].  To date, SMAD4 
mutations have been reported in 46 patients with Myhre syndrome (OMIM #139210) 
[Le Goff et al., 2012; Caputo et al., 2012; Lindor et al., 2012; Al Ageeli et al., 2012; 
Asakura et al., 2012; Picco et al., 2012; Ishibashi et al., 2014; Kenis et al., 2014; Michot 
et al., 2014; Hawkes et al., 2015; Oldenburg, et al., 2015] with no report of a familial 
case.   While the clinical picture of Myhre syndrome has been further clarified with new 
reports of molecularly proven cases, there remains a paucity of data on the 
cardiopulmonary aspects of the disorder, which may be progressive and fatal.  We 
report five new Myhre syndrome patients with SMAD4 mutations, three of whom died 
of severe cardiac disease, and provide delineation of the associated fibrotic 
complications.        
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CLINICAL REPORTS 
Patient 1 
The patient was born small for gestational age (SGA) at term to healthy, 
nonconsanguineous 29 year old parents.  When seen for initial genetic evaluation as a 
toddler she was noted to have progressive conductive hearing loss, mild developmental 
delay, dysmorphic craniofacial features, recurrent choanal stenosis, short stature, 
hyperopia, advanced bone age, 11 rib pairs, dermal thickening and compact build 
(Figure 1).  Echocardiogram at that time demonstrated a moderate-sized secundum 
atrial septal defect (ASD) but no valvar abnormalities.    Genetic studies at this time 
included a normal 46,XX karyotype, normal 180K microarray (hg 18), and normal 
CREBBP sequencing.   On routine cardiac followup at one year of age the patient was 
noted to have a small ASD and no other cardiac defects.  At seven years of age the 
patient was evaluated for a new murmur with symptoms of heart failure. 
Echocardiography at that time demonstrated polyvalvar thickening with moderate 
mitral valvar stenosis and normal subvalvar apparatus, mild mitral regurgitation, a 
trileaflet aortic valve with moderate aortic stenosis, mild aortic regurgitation, concentric 
left ventricular hypertrophy (LVH), mild tricuspid insufficiency and a diffusely small 
aortic arch without focal narrowing.  Further genetic studies included normal 
sequencing of ADAMTSL2 and FBN1 as well as deletion/duplication analysis.  Targeted 
sequencing of SMAD4 then revealed a c.1499T>C (p.Ile500Thr) mutation.   
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The patient developed rapid progression of her aortic stenosis and four months 
later underwent cardiac catheterization.  At catheterization, the valve appeared rubbery 
and dysplastic with easy resolution of narrowing on balloon inflation.  However, due to 
the rubbery nature of the valve, no reduction in gradient could be achieved with a 
standard-sized balloon.  A result was achieved after a second valvuloplasty with a larger 
balloon with a fall in the peak to peak gradient from 50 to 20 mmHg.  The improvement, 
however, was quite transient.  Both right and left ventricular end-diastolic pressures 
were elevated at 15mmHg, consistent with mild to moderate restrictive physiology.  
One month following the procedure the patient was again documented to have 
progressive aortic valvar stenosis as well as mitral stenosis.  Eight months following 
aortic valvuloplasty the patient underwent surgical aortic valve repair, tricuspid 
valvuloplasty, ASD closure and mitral valve replacement following a failed attempt at 
mitral valve repair.  The mitral valve was characterized by severe fibrosis and dystrophic 
calcification of the leaflets and subvalvar apparatus.  Aortic valvar, subvalvar and 
supravalvar fibrosis and calcification were also noted with fibrotic tissue partially 
covering the right coronary ostia.  The tricuspid valve was not fibrotic but had a 
dysplastic cleft in the anterior leaflet.  Surgery was complicated by complete heart block 
requiring pacemaker placement on postoperative day 10.  At the time of pacemaker 
placement the midline fascia below the sternotomy was noted to be abnormally 
thickened.  In addition, the epicardial surface of the heart was noted to be unusually 
rubbery and fibrotic.  Over the next two months the patient developed progressive 
heart failure secondary to a restrictive cardiomyopathy culminating in sudden cardiac 
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arrest and placement on extracorporeal membrane oxygenator (ECMO).  Left atrial 
pressure was markedly elevated at 35mmHg despite a functioning, appropriately-sized 
mechanical mitral valve.  Cardiac catheterization was performed for the purposes of 
creating an ASD for left heart decompression.  Left ventricular function remained 
severely impaired and the patient underwent cardiac transplantation.  Cardiac 
transplantation was complicated by inability to oxygenate requiring  ECMO support for 
one week, inability to obtain chest closure despite an appropriately-sized donor heart, 
progressive SVC anastomotic narrowing requiring stenting, respiratory failure with 
inability to wean from the ventilator, and progressive low cardiac output without 
evidence of rejection requiring repeat ECMO support two months post transplantation.  
The patient suffered an intracerebral bleed while on ECMO support and care was 
withdrawn.  She was eight years old.   
Patient 2:  
The patient was the second child of healthy, nonconsanguineous parents 
(maternal age 29 years; paternal age 37 years).  She was born SGA at term.  The 
pregnancy was complicated by polyhydramnios and prenatally diagnosed duodenal 
atresia.  The intestinal defect was repaired on the first day of life.  Routine 
echocardiogram demonstrated mild coarctation of the aorta.  The subsequent clinical 
course was characterized by dysmorphic craniofacial features (Figure 2), persistent short 
stature, velopharyngeal insufficiency requiring a palatal lengthening procedure, 
recurrent ear infections requiring placement of multiple sets of bilateral myringotomy 
tubes, and superimposed bilateral sensorineural hearing loss resulting in severe speech 
14 
 
delay.   Overall development was mildly delayed.  Skeletal survey showed a narrow 
sciatic notch, short metacarpals and 11 rib pairs.  At seven years of age the aortic 
coarctation was refractory to balloon angioplasty, for which she underwent stent 
placement. Despite adequate relief of aortic arch obstruction, the patient developed 
elevation in pulmonary vascular resistance and was subsequently diagnosed with 
restrictive cardiomyopathy, interstitial lung disease, and pulmonary hypertension.  
Pulmonary function testing revealed a severely reduced FEV1 with no response to 
bronchodilator therapy.  Open lung biopsy was performed at 10 years of age which   
demonstrated diffuse interstitial fibrosis, medial thickening of arteries, arterioles and 
veins and smooth muscle hyperplasia of the airways with a large amount of collagen 
present.  She had progression of her restrictive cardiomyopathy over a period of three 
years and underwent bilateral heart and lung transplantation.  Transplantation was 
complicated by diffuse mediastinal fibrosis (pericardium was noted to be normal) and 
adhesions requiring extensive care in removing.  Post-transplant her chest was able to 
be closed, however, she suffered persistent respiratory failure and blood pressure 
lability.  She suffered an ECMO-related stroke and died 6 days postoperatively at 12 
years of age.   
The explanted heart demonstrated no abnormality of the pericardium but 
diffuse fibrosis of the endocardium and subendocardium.  Explanted lungs 
demonstrated diffuse interstitial fibrosis with septal widening and pneumocyte 
hyperplasia.  SMAD4 sequencing performed post-mortem from previously extracted 
DNA for other genetic studies (46,XX karyotype, 22q11.2 FISH, chromosome breakage 
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studies, Feingold studies [MYCN sequencing and deletion/duplication analysis]), 
confirmed a c.1499T>C (p.Ile500Thr) mutation consistent with the diagnosis of Myhre 
syndrome.   
Patient 3:   
The patient was born SGA to nonconsanguineous parents at term (maternal age 
28 years; paternal age 30 years).  The clinical course was marked by dysmorphic 
craniofacial features (Figure 3)  significant feeding and swallowing difficulties as an 
infant.  At 24 months she charted at below the 5th centile for stature; approximately the 
50th centile for a 10 month old.  Her upper airway was thoroughly evaluated and no 
obstruction was found, although absent nasal cilia were noted.  Over time she had 
persistence of short stature, progressive conductive hearing loss, progressive skin 
changes marked by dermal thickening, menorrhagia refractory to medical therapy, and 
at age 17 presented with unilateral vision loss due to biopsy-confirmed right optic nerve 
sheath meningioma.  The patient had normal intelligence, but required medical 
treatment of obsessive-compulsive and anxiety disorders.  Her initial cardiac evaluation 
was performed at age two years at which time she was diagnosed with an innocent 
murmur with normal echocardiogram.  A repeat echocardiogram at age four years 
documented normal cardiac anatomy.  At age 16 she was again evaluated by cardiology 
for dyspnea and hypertension.  Spirometry revealed moderate to severe restrictive lung 
disease which was felt to be secondary to musculoskeletal deformity due to her 
dwarfism.  Echocardiogram documented mild aortic stenosis and normal ventricular 
function.  Hypertension was well controlled on two medical agents.   
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Over a period of eight years her aortic valve stenosis became progressively more 
severe with a peak to peak gradient of 80 mmHg.  Aortic balloon valvuloplasty was 
performed.  This also required upsizing of the balloon, with the valve appearing 
dysplastic.  A reduction in gradient from 80 to 35 mmHg was achieved.  The patient had 
persistent elevation of both right- and left-sided filling pressures consistent with 
restrictive physiology.  Myhre syndrome was diagnosed at this time with confirmation of 
a c.1498A>G (p.Ile500Val) mutation in SMAD4.  Over the ensuing two years the patient 
developed progressive shortness of breath with LVH and progressive aortic stenosis 
requiring repeat valvuloplasty attempt at age 26 years.  Just prior to her catheterization 
she was unable to walk across the room or eat a meal without distress.  At 
catheterization, the anesthesia team found her respiratory mechanics to be significantly 
compromised and counselled the family that she may not tolerate extubation.  The 
catheterization documented progressive aortic stenosis (gradient of 78mmHg), and 
marked elevation in diastolic pressures in both ventricles.  The intervention produced 
minimal improvement in the aortic valve (reduction to 55mmHg), despite two larger 
balloon attempts.  No aortic insufficiency was created. She was transferred to the ICU, 
but was unable to wean from mechanical ventilation.  After discussion with her family 
regarding her severely compromised cardiac and lung function, her family elected not to 
proceed with resuscitation; when she received an optimized trial of extubation, she was 
unable to maintain adequate ventilation and died.   
Patient 4:   
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The patient was born SGA 3 days prior to due date to 26 year old 
nonconsanguineous parents.  He had poor feeding, gastroesophageal reflux, and 
subglottic stenosis.  His motor development was mildly delayed and at two years of age 
bilateral hearing loss was found on evaluation for delayed speech.  He was found to be 
growth hormone deficient and placed on growth hormone at age eight.  Since starting 
growth hormone he has progressed from the 5th centile to the 30th centile for height (at 
13 years of age).  He had seen genetics at seven years of age for evaluation of 
dysmorphic craniofacial features (Figure 4a-c), hypotonia, hearing loss, restricted finger 
joint movement (Figure 4d), and short stature which resulted in a normal microarray 
and Noonan syndrome testing.  At nine years of age he underwent choanal stenosis 
repair. Spirometry demonstrated persistent restrictive lung disease without response to 
albuterol.  He had a diagnostic right deltoid muscle biopsy which showed small striated 
muscle fibers of minimal size variation.  Histologic analysis showed esterase-positive 
cellularity within the epimysial connective tissue.  The biopsy site required several 
weeks to heal and resulted in a large fibrotic scar (Figure 4e).  He had normal 
echocardiograms at 6 and 11 years of age.  On follow up with genetics, at 11 years of 
age he was recognized to have findings of Myhre syndrome; SMAD4 targeted testing 
confirmed a c.1498A>G (p.Ile500Val) mutation.  By 13 years of age he had a total of nine 
sets of myringotomy tubes and continues to have restrictive pulmonary disease but 
otherwise well, and is attending school full time. 
Patient 5:   
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The fifth patient was born SGA at 37 weeks gestation to healthy 
nonconsanguineous parents (maternal age 25 years; paternal age 28 years) with a 
noncontributory family history.  On clinical genetics evaluation at four years of age she 
was noted to have dysmorphic craniofacial features (Figure 5a-c), bilateral hearing loss 
(right ear primarily conductive; left ear mixed), strabismus, velopharyngeal insufficiency, 
asthma, gastroesophageal reflux, prior gastric fundoplication, mild periventricular 
leukomalacia, limited joint extensibility, and speech and gross motor delays.  She had 
normal social development and intelligence.  At that time height was 94 cm, (3rd 
centile), weight was 14.2 kg (10th centile) and head circumference was 50.1 cm (45th 
centile).  She had a flat nasal bridge, a systolic murmur, and limited movement of the 
joints.  Subsequent clinical course was significant for tonsillectomy and adenoidectomy 
at age seven years.   At age eight years she underwent a superiorly based pharyngeal 
flap and was noted to have vocal cord paresis and subglottic stenosis with scarring of 
the vocal cords.    She was found to have fusion of the C6 and C7 vertebral bodies with 
widening of the C5-C6 disc space (Figure 5d).  She was diagnosed with systemic 
hypertension and suffered multiple episodes of otitis media and pneumonias with 
pleural effusion.  She had hypogammaglobulinemia with recurrent variable infections 
which has responded to IVIG treatment.    
At 12 years of age she presented with cough and positional dyspnea.  
Echocardiogram demonstrated a very large pericardial effusion and severe reduction in 
left ventricular systolic function with shortening fraction of 10%.  Ventricular chambers 
were normal in size but both atria were dilated.    Following drainage of her pericardial 
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effusion her ventricular function remained poor with evidence of abnormal diastolic 
function with an E/A ratio > 3:1.  During this evaluation intubation required multiple 
attempts and special measures.  She was transferred to a tertiary care center for 
consideration of advanced heart failure therapies.  She was diuresed and started on 
inotropic support with recovery of ventricular function within 24 hours.  One year later 
the patient developed diffuse edema and dyspnea.  Evaluation at that time 
demonstrated normal sized ventricles with preserved systolic function, dilated atria, 
abnormal mitral inflow as noted previously, a small pericardial effusion, and elevated 
BNP consistent with constrictive or restrictive physiology.  As part of her vascular 
workup for chronic hypertension, she was noted to have a diffusely small descending 
aorta and focal stenosis of the celiac artery.  At 13 years of age, the patient developed 
progressive sublaryngeal stenosis and a tracheostomy was performed.  At followup she 
was noted to have a shelf of scar tissue with complete soft tissue stenosis of the airway.  
Both her fundoplication (Figure 5e) and tracheostomy incisions resulted in a 
hypertrophic scar.  
Normal genetic studies throughout her course included an amniocentesis 46,XX 
karyotype, 22q11.2 FISH, subtelomere FISH, and microarray analysis (2013).  At 14 years 
of age SMAD4 sequencing showed a c.1499T>C (p.Ile500Thr) mutation.     
At 15 years of age the patient continues to have significant issues with severe 
subglottic stenosis that had progressed to grade IV, resulting in inability to vocalize; 
evaluation for laryngotracheal reconstruction was in process.   
20 
 
DISCUSSION 
Myhre syndrome is caused by apparent gain-of-function mutation in SMAD4 
which, to date, appear to be restricted to heterozygous missense changes in Ile500 
within the conserved MAD homology 2 domain of exon 11 [Caputo et al., 2012; LeGoff 
et al., 2012; LeGoff, et al., 2014] in all but three reported patients.  In these three 
patients with a clinical phenotype of Myhre syndrome, an Arg496 change [Caputo et al., 
2014; Michot et al., 2014] was instead documented.  These patients were of normal 
stature and did not have cardiac anomalies.  While the Arg496 residue is involved in the 
transcriptional activation of SMAD4 it only results in dysregulation via altered 
expression of matrix metalloproteinases (MMPs) which act as a major contributor to 
extracellular matrix (ECM) stability [Caputo et al., 2014; Piccolo et al., 2014].  In contrast, 
the more typical Ile500 aberrations affect the MMPs as well as their related inhibitors 
[Piccolo et al., 2014].   
In Myhre syndrome, because of decreased mono-ubiquitination, stability is 
inferred upon the SMAD4 protein which disrupts TGFβ signaling, resulting in abnormal 
development of axial and appendicular skeletal structures, skeletal and cardiac muscular 
development as well as the central nervous system [Caputo, 2012; Le Goff, 2014].  The 
role of the SMADs has been well established in a spectrum of acquired cardiac diseases, 
including cardiac fibrosis and hypertrophy, aortopathies, atherogenesis and pulmonary 
artery hypertension.  SMAD4, a central cytoplasmic mediator of the TGF-β and BMP 
signaling pathways, has been shown to have increased expression in patients with 
cardiac atrial fibrosis [Gramley et al., 2010].    
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Although there has not been a Myhre syndrome-specific mouse model, there 
have been other mouse models looking at the role of SMAD4 as it relates to cardiac 
form and function.  A mouse model with cardiac myocyte-specific disrupted SMAD4 
developed heart failure secondary to significant cardiomyocyte hypertrophy and cardiac 
fibrosis [Wang et al., 2005].  Cardiac tissue fibrosis has also been induced in cardiac 
fibroblasts from a mouse model directly targeting SMAD4, increasing the profibrogenic 
TGF- β1 activity [Huang et al., 2014]. A keratinocyte-specific SMAD4 knockout mouse 
has been shown to have a significantly accelerated rate of keratinocyte proliferation and 
wound contraction [Yang et al., 2012]. 
We present five previously unpublished patients with Myhre syndrome with 
documented SMAD4 missense mutations in the isoleucine residue at position 500 (Table 
I).  While all share cardinal features of progressive hearing loss, restricted joint 
movement, thick skin, and compact habitus, they also demonstrate impressive 
variability in clinical expression.  We are not aware of any prior reports of need for 
cardiac transplantation in this patient population.  While minor cardiac involvement has 
been reported in many patients with Myhre syndrome the need for and outcome of 
surgical intervention, has not been thoroughly described.  Constrictive pericarditis has 
been reported  in LAPS (Laryngotracheal stenosis, Arthropathy, Prognathism, and Short 
stature) syndrome, a condition determined to be a phenotypic variant of Myhre 
syndrome by Lindor et al. in 2012 [Picco et al., 2013; Michot et al., 2014]. In Lindor’s 
series, one patient who underwent pericardectomy for presumed constrictive 
pericarditis, had persistent restrictive indices on echocardiography suggesting that 
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restrictive cardiomyopathy may have been the underlying disease process as it was in 
the four patients we describe with cardiomyopathy.   
Specifically, Myhre syndrome patients undergoing transplantation have not been 
previously reported and we present two patients who were unable to survive post-
transplantation complications.  These patients had significant fibrotic scarring of the 
heart itself and surrounding mediastinal structures from presumed previous tissue 
damage or instrumentation.  Of note, the pericardium itself was noted to be normal in 
these three patients where the pericardium was inspected intraoperatively or on 
autopsy.  This article highlights a potential deleterious effect of surgery in these patients 
with abnormal tissue response resulting in impaired wound healing, anastamotic 
strictures, and adverse myocardial remodeling.  Prior concern about wound healing in 
Myhre syndrome was raised by Lindor et al, noting life-threatening adhesions following 
hysterectomy in a patient who also had chronic restrictive cardiomyopathy which 
persisted after pericardectomy [Lindor et al., 2012].   
In addition, Myhre syndrome patients are prone to complicated airway 
management.  Post-intubation/tracheal-trauma fibrotic scarring resulting in grade IV 
stenosis is presumed in Patient 5 and has also been reported in multiple other patients 
with Myhre syndrome [Oldenburg et al., 2015] and we recommend extraordinary 
caution with intubation.   
The decision to take a patient with Myhre syndrome to surgery of any kind 
should include a discussion of an apparently abnormal wound healing process, abnormal 
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adhesions and fibrosis that could impact overall success and both short- and long-term 
morbidity and mortality.  The potential for current and future difficult airway 
management should also be reviewed.  For all Myhre syndrome patients, serial 
echocardiograms should be performed to detect progressive valvar and myocardial 
disease.  We recommend an echocardiogram at the time of diagnosis of Myhre 
syndrome and at a minimum of every two years thereafter or if symptoms arise.  In 
addition, prompt referral for pulmonary evaluation with functional testing should be 
performed if symptoms suggest compromise, due to the increased risk for restrictive 
pulmonary insufficiency.  Patients with Myhre syndrome should be closely monitored 
post-operatively for abnormal fibrotic wound healing and elective surgical procedures 
should be avoided if at all possible given the attendant risks.       
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TABLE 
TABLE I.  Clinical details and newly reported features of the patients reported in this 
manuscript.   
 
*hearing loss, typical facial features, compact build, restricted joint movement, thick 
skin 
  
Patien
t 
Age in 
years 
Cardinal 
Features* 
SMAD
4  Sex 
Paterna
l age 
Cardio/ 
pulmon
ary 
restricti
ve 
disease 
Newly reported 
features  
1 
8 
(deceas
ed) + I500T F 29 +/? 
post-transplant 
(heart) 
complications 
2 
12 
(deceas
ed) + I500T F 37 +/+ 
duodenal 
atresia, post-
transplant 
(heart and lung) 
complications 
3 
26 
(deceas
ed) + I500V F 30 +/+ 
optic nerve 
sheath 
meningioma 
4 
13 (at 
time of 
report) + I500V M 26 -/+ 
favorable 
response to 
growth 
hormone 
5 
15 (at 
time of 
report) + I500T F 28 +/+ 
hypogammaglo
bulinemia 
resolved with 
IVIG treatment 
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FIGURES and LEGENDS 
 
FIG 1.  Patient one at seven years of age.  Note midfacial retrusion, relative prognathism, 
flat nasal bridge, downward pointing nasal tip, microstomia, wide-spaced teeth, thin 
upper lip, broad ears with a squared shape, limited facial creasing, broad and short neck 
with an overall compact body habitus.   She has brachydactyly and fingers are not 
CApable of full extension.   
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FIG 2.  Photos of the patient 2 at 1, 2, 3, 5, 10 (standing) and 12 years of age.  Note 
progression of features with midfacial retrusion, prognathism, flat nasal bridge, 
downward pointing nasal tip, microstomia, thin upper lip, broad ears with a squared 
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shape, limited facial creasing, broad and short neck with compact body habitus.   
 
FIG 3.  Photos of patient 3 at 23 years of age.  Note midfacial retrusion, flat nasal bridge, 
downward pointing nasal tip, microstomia, thin upper lip, prognathism, broad ears with 
a squared shape, limited facial creasing, broad neck and low posterior hairline.  
Brachydactyly with limited extension and lordosis is also present.  
 
28 
 
FIG 4a-d.  Photos of patient 4 at 7 (a) and 11 (b,c) years of age.  Note the mild features 
of this patient.   Broad and flat nasal bridge, mild midfacial retrusion with relative 
prognathism.  Mild brachydactyly is present with limited small and large joint extension 
(d).       
FIG 4e.  Hypertrophic scar subsequent to uncomplicated muscle biopsy.   
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FIG 5a-c.  Photos of patient 5 at 3 and 15 years of age.  Note progression of midfacial 
retrusion and prognathism.  This patient has a lateral ptosis, low hanging columella, 
square and broad ears and minimal facial creasing. 
FIG 5d.  Radiograph of cervical vertebrae at 11 years of age show an anterior bar fusing 
C2 to C3 and fusion of the C6 and C7 vertebral bodies with widening of the C5-C6 disc 
space.  
FIG 5e.  Hypertrophic scars at fundoplication incision site.   
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Summary 
Clinical characteristics. 
Myhre syndrome is a connective tissue disorder with multisystem involvement, progressive and 
proliferative fibrosis that may occur spontaneously or following trauma or surgery, mild-to-
moderate intellectual disability, and in some instances, autistic-like behaviors. Organ systems 
primarily involved include: cardiovascular (congenital heart defects, long- and short-segment 
stenosis of the aorta and peripheral arteries, pericardial effusion, constrictive pericarditis, 
restrictive cardiomyopathy, and hypertension); respiratory (choanal stenosis, laryngotracheal 
narrowing, obstructive airway disease, or restrictive pulmonary disease), gastrointestinal 
(pyloric stenosis, duodenal strictures, severe constipation); and skin (thickened particularly on 
the hands and extensor surfaces). Additional findings include distinctive craniofacial features 
and skeletal involvement (intrauterine growth restriction, short stature, limited joint range of 
motion). To date, 55 individuals with molecularly confirmed Myhre syndrome have been 
reported. 
Diagnosis/testing. 
The diagnosis of Myhre syndrome is established by detecting a de novo SMAD4 heterozygous 
pathogenic variant in a proband with characteristic clinical findings. 
Management. 
Treatment of manifestations: Symptomatic treatment (with attention to limiting tissue trauma 
by minimizing instrumentation during diagnosis and management) by specialty experts of the 
following involvement: cardiovascular, respiratory (including tracheostomy when tracheal 
32 
 
stenosis is recurrent or complete), and GI; routine management of speech and language delay, 
intellectual disability, behavioral problems. 
Prevention of secondary complications: Limiting of tissue trauma given the apparent increased 
risk for proliferative fibrosis following otherwise uncomplicated endotracheal intubation and 
surgical procedures. When possible, alternative noninvasive approaches should be pursued 
during diagnosis and management 
Surveillance: Cardiovascular: echocardiogram every one to three years in asymptomatic 
individuals with a normal echocardiogram at the time of initial diagnosis; in individuals with 
abnormal cardiac findings at the time of diagnosis, more extensive imaging (including possible 
cardiac MRI) may be considered. Respiratory: oxygen saturation in children with monitoring as 
needed for symptoms suggestive of restrictive/obstructive pulmonary disease; annual 
pulmonary function studies in children oldert than age six years if able to cooperate; evaluation 
of laryngotracheal stenosis based on symptoms. Annual ophthalmology and audiology 
evaluations. 
Agents/circumstances to avoid: Smoking; tissue trauma. 
Genetic counseling. 
Myhre syndrome is inherited in an autosomal dominant manner. All probands with Myhre 
syndrome reported to date have the disorder as a result of a de novo SMAD4 pathogenic 
variant. If the SMAD4 pathogenic variant found in the proband cannot be detected in the 
leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of 
the general population (though still <1%) because of the theoretic possibility of parental 
germline mosaicism. To date, individuals with Myhre syndrome are not known to reproduce and 
fertility has not been assessed. Once the SMAD4 pathogenic variant has been identified in an 
affected family member, prenatal testing for a pregnancy at theoretic increased risk for Myhre 
syndrome and preimplantation genetic diagnosis are possible. 
Diagnosis 
Formal diagnostic criteria have not been published for Myhre syndrome. 
Suggestive Findings 
Myhre syndrome should be suspected in individuals with the following clinical and radiographic 
findings. 
Clinical 
Cardiovascular 
Arterial obstruction: juxtaductal coarctation of the aorta, long- and short-segment descending 
thoracic and abdominal aortic obstruction, and peripheral arteries in various locations; 
infrequently, branch pulmonary artery stenosis 
Congenital heart defects: 
Atrial and ventricular septal defects, patent ductus arteriosus 
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Valvular stenosis: aortic and mitral valves; infrequently, tricuspid and pulmonic valves 
Pericardial involvement: ranges from effusion to constrictive pericarditis; often chronic and 
severe 
Restrictive cardiomyopathy (can be rapidly progressive) 
Hypertension: systemic and pulmonary 
Respiratory (congenital or acquired) 
Laryngotracheal narrowing (including subglottic stenosis) 
Choanal stenosis 
Obstructive airway disease 
Restrictive pulmonary disease (which appears to increase with age) 
Gastrointestinal 
Congenital or acquired pyloric stenosis 
Later onset: 
Duodenal strictures 
Severe constipation 
Skin 
Stiff and thickened overall, but particularly on the hands and extensor surfaces 
Facial creases fewer than expected for age 
Proliferative fibrosis/scarring 
May occur spontaneously or following trauma or surgery 
May involve the serosal surfaces of the heart, airway and lungs, and gastrointestinal tract as well 
as the skin 
Neuropsychiatric 
Mild-to-moderate intellectual disability 
Autistic-like behaviors in some 
Craniofacial 
Characteristic facial features including short palpebral fissures, deeply set eyes, maxillary 
underdevelopment, short philtrum, narrow mouth, thin vermilion of the upper lip, and 
prognathism (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5). Facial characteristics can progress 
over time; although classic coarsening of features is not present, mandibular elongation is 
notable. Note: Craniofacial features can vary considerably. 
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Cleft lip and/or palate and velopharyngeal insufficiency reported in 13% [Lin et al 2016] 
 
Figure 1. 
Female with Myhre syndrome at ages seven months, four years, and 16 years. Note the short 
palpebral fissures, thin upper vermilion border and maxillary underdevelopment. She required 
tracheostomy subsequent to traumatic intubations that resulted in complete tracheal stenosis 
 
Figure 2. 
Female with Myhre syndrome at ages newborn, 12 months, 3.5 years, and seven years. Note the 
short palpebral fissures, thin upper vermilion border, and progression of mild prognathism. 
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Figure 3. . Female with Myhre syndrome at ages three years, ten years (standing), and 21 years 
(face, posterior hairline, and hands). 
Female with Myhre syndrome at ages three years, ten years (standing), and 21 years (face, 
posterior hairline, and hands). Note the short palpebral fissures, broad mid-upper nasal bridge, 
downward pointing nasal tip, thin upper vermilion border, broad and short neck, contracted 
joints (elbows are fully extended in photos), brachydactyly, and compact habitus. 
 
Figure 4. 
Male with Myhre syndrome at age 12 years. Note the mild facial features (mild maxillary 
underdevelopment and thin upper vermilion border) and finger contractures (hands are on a 
flat surface). 
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Figure 5. . Female with Myhre syndrome at age five years. 
Female with Myhre syndrome at age five years. Note the short palpebral fissures, thin upper 
and lower vermilion borders, left-sided facial palsy, and brachydactyly with otherwise mild 
features. Facial palsy is observed in 4% of individuals with Myhre syndrome [Lin et al 2016]. 
Skeletal 
Infants typically have intrauterine growth restriction (IUGR) 
Short stature (height is significantly less than that predicted by parental heights) with compact 
body habitus 
Range of motion of the joints can be limited 
Radiographic 
Findings include the following: 
Thickened calvarium 
Shortened long bones 
Brachydactyly 
Broad ribs 
Enlarged vertebrae with shortened pedicles; vertebral fusion 
Hypoplastic iliac wings 
See Figure 6. 
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Figure 6. 
Radiographs of a female age 14 years A. Thickened calvaria and anterior cervical vertebral fusion 
(arrow) of C2 and C3 
Establishing the Diagnosis 
The diagnosis of Myhre syndrome is established in a proband with characteristic clinical findings 
and a de novo heterozygous pathogenic variant in SMAD4 detected by molecular genetic testing 
(see Table 1). 
Molecular genetic testing approaches can include a combination of gene-targeted testing 
(multigene panel or single-gene testing) and genomic testing (comprehensive genome 
sequencing). 
Gene-targeted testing requires the clinician to determine which gene(s) are likely involved, 
whereas genomic testing may not. Persons with the distinctive findings described in Suggestive 
Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in 
whom a specific diagnosis has been elusive are more likely to be diagnosed using genomic 
testing (see Option 2). 
Option 1 
When the phenotypic and radiographic findings suggest the diagnosis of Myhre syndrome, 
molecular genetic testing approaches can include single-gene testing or use of a multigene 
panel: 
Single-gene testing. Sequence analysis of SMAD4 is performed first. If no pathogenic variant is 
found, gene-targeted deletion/duplication analysis may be considered; to date, however, no 
exon or whole-gene deletions have been reported. 
A multigene panel that includes SMAD4 and other genes of interest (see Differential Diagnosis) 
may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity 
of the testing used for each gene vary by laboratory and over time. (2) Some multigene panels 
may include genes not associated with the condition discussed in this GeneReview; thus, 
clinicians need to determine which multigene panel is most likely to identify the genetic cause of 
the condition at the most reasonable cost while limiting identification of variants of uncertain 
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significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) 
In some laboratories, panel options may include a custom laboratory-designed panel and/or 
custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) 
Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or 
other non-sequencing-based tests. 
For an introduction to multigene panels click here. More detailed information for clinicians 
ordering genetic tests can be found here. 
Option 2 
When the diagnosis of Myhre syndrome has not been considered, genomic testing 
(comprehensive genome sequencing), when available, is likely to be the diagnostic modality 
selected. Comprehensive genome sequencing includes exome sequencing and genome 
sequencing. 
For an introduction to comprehensive genomic testing click here. More detailed information for 
clinicians ordering genomic testing can be found here. 
Table 1. 
Molecular Genetic Testing Used in Myhre Syndrome 
Gene 1 Test Method 
Proportion of Probands with a Pathogenic 
Variant 2 Detectable by This Method 
SMAD4 
Sequence analysis 3 55/55 4 
Gene-targeted deletion/duplication 
analysis 5 
Unknown 6 
1. See Table A. Genes and Databases for chromosome locus and protein. 
2. See Molecular Genetics for information on allelic variants detected in this gene. 
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; 
typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence 
analysis results, click here. 
4. 54 patients summarized by Lin et al [2016] and one patient reported by Bassett et al [2016] 
5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include: quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications. 
6. No data on detection rate of gene-targeted deletion/duplication analysis are available. 
 
Clinical Description 
Myhre syndrome is a multisystem connective tissue disorder involving: the cardiovascular 
system, respiratory system, gastrointestinal tract, and skin; progressive and proliferative fibrosis 
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that may occur spontaneously or following trauma or surgery, often resulting in significant 
complications; mild-to-moderate intellectual disability; and behavioral issues in some. 
Additional findings include distinctive craniofacial features and skeletal involvement. 
Myhre syndrome was first described by Myhre et al [1981] in two unrelated males. Since 2011, 
when heterozygosity for a SMAD4 pathogenic variant was found to be causative, 55 affected 
individuals with a molecularly confirmed diagnosis of Myhre syndrome have been reported. Lin 
et al [2016] reported four affected individuals and summarized findings in 50 previously 
reported individuals [Le Goff et al 2011, Al Ageeli et al 2012, Asakura et al 2012, Caputo et al 
2012, Lindor et al 2012, Picco et al 2013, Ishibashi et al 2014, Kenis et al 2014, Michot et al 2014, 
Hawkes & Kini 2015, Oldenburg et al 2015, Starr et al 2015]. Subsequently Bassett et al [2016] 
reported one additional affected individual. 
Note: Unless otherwise noted, the following findings are reported in Lin et al [2016]. 
Infancy and progression of findings. In infancy, characteristic facial features are usually present, 
but more difficult to recognize than in an older child (see Suggestive Findings and Figure 1, 
Figure 2, Figure 3, Figure 4, Figure 5). Short stature and hearing loss develop over time as well as 
the highly distinctive (and often severe) findings of Myhre syndrome: joint stiffness, restrictive 
lung and cardiovascular disease, progressive and proliferative fibrosis, and thickening of the 
skin. 
Cardiovascular. Of 54 individuals with a confirmed molecular diagnosis of Myhre syndrome, 70% 
had a cardiovascular abnormality including structural heart defects (63%); pericardial disease 
(17%), restrictive cardiomyopathy (9%), and systemic hypertension (15%). 
Cardiovascular abnormalities include the following: 
Atrial septal defect (4%) and ventricular septal defect (6%) 
Patent ductus arteriosus (which can be large) (20%) 
Obstructive defects of the left heart, such as juxtaductal aortic coarctation (15%), long-segment 
aorta narrowing (6%), aortic valve stenosis (15%), and mitral valve stenosis (2%). These are more 
common than obstructive defects of the right-side, such as valvar and branch pulmonary artery 
stenosis [Michot et al 2014, Hawkes & Kini 2015, Starr et al 2015]. 
Peripheral vascular stenoses (in celiac and/or renal arteries) (7%) 
Of note, complex congenital heart defects are not observed. 
Pericardial disease (reported in 17%) can present as a short-term or recurrent effusion or as 
chronic or progressive constrictive pericarditis that may require surgical intervention (see 
Management). 
Restrictive cardiomyopathy, a lethal condition, is the least common form of cardiomyopathy in 
the general population and can be overlooked unless cardiac catheterization documents the 
characteristic hemodynamics. 
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While constrictive pericarditis and restrictive cardiomyopathy can present with similar 
hemodynamics, they differ in pathogenesis and treatment (see Management). 
Pulmonary hypertension has been infrequently reported; however, this may reflect limited 
evaluation and/or bias toward ascertainment and/or reporting of younger patients (as 
underlying causes of pulmonary hypertension resulting from involvement of the lungs and 
cardiovascular circulation may evolve with age). 
Progressive cardiovascular issues can appear at any age; those with onset in childhood may 
worsen following instrumentation: two patients with restrictive cardiomyopathy who were 
treated with heart and heart/lung transplantation did not survive postoperative complications 
[Starr et al 2015]. 
Respiratory. Respiratory issues can be multifactorial. Airway stenosis, typically involving the 
larynx and trachea, has included subglottic stenosis (17%) that can be recurrent and severe. Less 
common is upper airway obstruction due to choanal stenosis (11%). 
Restrictive and obstructive pulmonary disease are major causes of morbidity at all ages. 
Interstitial lung disease has been described. Severe pulmonary fibrosis has been noted on 
autopsy [Starr et al 2015]. 
Gastrointestinal involvement 
Duodenal atresia 3/54 (6%) 
Late-onset pyloric stenosis [L Starr, personal observation] 
Protein-losing enteropathy (Patient 1 [Lin et al 2016]) 
Severe constipation [Michot et al 2014, Starr et al 2015] 
Cutaneous. Generalized thickening/stiffness of the skin is seen in nearly all individuals with 
Myhre syndrome. Various terms used to describe the skin include thick, stiff, firm, rough, 
keratotic, and inelastic. Additional findings are minimal creasing of the facial skin and fibrous 
and keloid-like scar formation. 
Skin changes may not be apparent in infancy; they are often first noted on extensor surfaces, 
palms, and soles. The changes progress with age. 
Neuropsychiatric. Data are limited. Mild-to-moderate intellectual disability and global 
developmental delay are common; however, cognition can be within the normal range. Of note, 
acquired and unrecognized hearing loss may also contribute to speech delay and academic and 
social challenges. 
Findings of autism spectrum disorder have been noted in a minority of affected individuals 
[Michot et al 2014]. 
Skeletal. The majority of affected infants have intrauterine growth restriction (41/49; 84%). 
Short stature with compact body habitus (with normal head circumference) becomes more 
apparent over time. Adult height is expected to be more than two standard deviations below 
what is predicted by parental heights. 
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Small hands and feet with brachydactyly is usually notable (see Figure 3, Figure 4, Figure 5). 
Posture may be distinct with flexed elbows and bending forward at the hips (see Figure 3 and 
Ishibashi et al [2014], Figure 1). 
Reduced range of motion of large and small joints is characteristic and is exacerbated with age. 
Walking on tiptoes is common. 
Immune system. Recurrent infections (especially otitis media and pneumonia) have been 
reported in 19 of 34 individuals. Increased susceptibility to infection has been associated with 
immunoglobulin deficiency in three affected individuals; IVIG was utilized with reported benefit 
in one affected individual [Starr et al 2015]. At this point, it is unknown if immune deficiency is 
associated with Myhre syndrome or if it is an incidental finding [Michot et al 2014, Starr et al 
2015]. 
Ophthalmologic. At least one abnormal eye finding was reported in 53% (26/49) of affected 
individuals: 
Strabismus 13/53 (24%) 
Refractive errors in 17/53 (31%) 
Other. Cataracts, astigmatism, and optic nerve sheath meningioma 
Hearing loss is observed in most (83%) individuals with Myhre syndrome. 
Hearing loss is predominantly conductive, but can be sensorineural and mixed. The underlying 
etiology of the hearing loss is often unclear or unknown; most often patients have a history of 
bilateral myringotomy tube placement. 
Of note, most infants pass their newborn hearing screen. In the authors' experience hearing loss 
usually becomes evident in early childhood and is typically present in adults. 
Endocrine. Puberty has been reported to be normal, premature, or delayed. Secondary 
amenorrhea has been reported. 
Neoplasia 
Endometrial carcinoma [Lindor et al 2012], optic nerve sheath meningioma [Starr et al 2015], 
and mesencephalic glioma [Lin et al 2016] have each been reported once. 
Telangiectasias and juvenile polyps, reported in heterozygotes for a SMAD4 loss-of-function 
pathogenic variant, have not been reported in Myhre syndrome; however, information to date 
is limited. 
Genotype-Phenotype Correlations 
The gain-of-function SMAD4 pathogenic variants that cause Myhre syndrome involve only two 
protein residues (codons 496 and 500). To date, no clear genotype-phenotype correlations are 
evident in affected individuals with either codon abnormality. 
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Of note, although the three individuals reported with the p.Arg496C variant do not have 
cardiovascular involvement and are taller in stature – two on the growth curve (2nd-25th 
centile) and one <1st centile [Michot et al 2014, Caputo et al 2014] – the data are too limited to 
draw any conclusions about genotype-phenotype correlations. 
Penetrance 
Penetrance appears to be complete; however, no familial cases of Myhre syndrome have been 
reported. 
Nomenclature 
LAPS (laryngotracheal stenosis, arthropathy, prognathism, and short stature) syndrome was 
determined to be a phenotypic variant of Myhre syndrome with pathogenic variants in the same 
codons [Lindor et al 2012, Picco et al 2013, Michot et al 2014]; the term is no longer in use. 
Prevalence 
The prevalence is unknown. 
Since 2011 when a heterozygous pathogenic variant in SMAD4 was discovered to be the cause 
of Myhre syndrome, 55 affected individuals with a molecularly confirmed diagnosis have been 
reported worldwide with no apparent ethnic or sex predilection (54 summarized in Lin et al 
[2016] and one reported by Bassett et al [2016]). 
Genetically Related (Allelic) Disorders 
Other phenotypes known to be associated with germline pathogenic variants in SMAD4: 
Juvenile polyposis syndrome (JPS) 
Hereditary hemorrhagic telangiectasia (HHT) 
Whereas Myhre syndrome is caused by heterozygous gain-of-function SMAD4 pathogenic 
variants (see Molecular Genetics), JPS and HHT are caused by heterozygous loss-of-function 
SMAD4 pathogenic variants. 
Differential Diagnosis 
The disorders that most closely resemble Myhre syndrome are the other acromelic dysplasias: 
geleophysic dysplasia, acromicric dysplasia, and Weill-Marchesani syndrome, which share the 
findings of thickened skin, short stature, short hands, and stiff joints. MULIBREY nanism should 
also be considered. 
Table 2. 
Disorders to Consider in the Differential Diagnosis of Myhre Syndrome 
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Disorder Gene(s) MOI 
Clinical Features of the Disorder 
Overlapping with Myhre 
Syndrome 
Distinguishing from Myhre 
Syndrome 
Acromicric 
dysplasia 
(OMIM 102370) 
FBN1 AD 
 IUGR 
 Short stature 
 Brachydactyly 
 Joint stiffness 
 Thickened skin 
 Characteristic 
external notch of 
the fifth 
metacarpal and 
internal notch of 
the femoral head 
 Absence of hearing 
loss 
 Less frequent 
cardiac anomalies 
 Absence of 
calvarial thickening 
Geleophysic 
dysplasia 1 
ADAMTSL2 AR 
 IUGR 
 Short stature 
 Short hands and 
feet 
 Progressive joint 
limitation and 
contractures 
 Progressive 
cardiac valvar 
thickening 
 Thickened skin 
 Hepatomegaly 
 Characteristic 
facies 
FBN1 AD 
Weill-
Marchesani 
syndrome 2 
ADAMTS10 
LTPBP2 
AR  IUGR 
 Short stature 
 Brachydactyly 
 Joint stiffness 
 Distinctive lens 
abnormalities 2 
 Lack of hearing 
loss 
FBN1 AD 
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Disorder Gene(s) MOI 
Clinical Features of the Disorder 
Overlapping with Myhre 
Syndrome 
Distinguishing from Myhre 
Syndrome 
MULIBREY 
nanism 
(OMIM 253250) 
TRIM37 AR 
 IUGR 
 Short stature 
 Relatively large 
head 
 Constrictive 
pericarditis 
 Restrictive 
cardiomyopathy 
 Shorter stature 
 Small tongue 
MOI = mode of inheritance 
AD = autosomal dominant 
AR = autosomal recessive 
XL = X-linked 
IUGR = intrauterine growth restriction 
1. 
Geleophysic dysplasia. Major findings are likely to be present in the first year of life. Cardiac and 
respiratory involvement result in death before age five years in approximately 33% of individuals 
with geleophysic dysplasia 1. 
2. 
Weill-Marchesani syndrome. The ocular problems, typically recognized in childhood, include 
microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, 
ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness 
 
Management 
Evaluations Following Initial Diagnosis 
To establish the extent of disease and needs in an individual diagnosed with Myhre syndrome, 
the following are recommended (if not completed previously as part of the diagnostic 
evaluation). 
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Cardiovascular 
Upper- and lower-extremity blood pressure measurements 
Two-dimensional echocardiography with Doppler 
For those with abnormal findings, more extensive imaging if indicated including cardiac 
catheterization to document the characteristic hemodynamics of restrictive cardiomyopathy 
Respiratory 
Assessment for airway stenosis by the least invasive means possible with assessment for signs of 
upper-airway obstruction including noisy breathing, work of breathing, and oxygen saturation 
Assessment of pulmonary function and oxygen saturation for evidence of obstructive or 
restrictive lung disease 
Gastrointestinal. Based on clinical indication (by least invasive means possible), evaluate for 
evidence of stenosis. 
Neuropsychiatric. Neuropsychometric evaluation may be indicated for individuals with autistic 
behaviors and/or cognitive involvement. 
Other 
Ophthalmology evaluation 
Speech evaluation 
Audiology evaluation 
Consultation with a clinical geneticist and/or genetic counselor 
Treatment of Manifestations 
Treatment is largely symptomatic and may include the following. 
Cardiovascular 
Management by a cardiologist trained in congenital heart disease, including pericardial disease 
and restrictive cardiomyopathy. At present, no evidence suggests that in Myhre syndrome 
management of specific lesions would differ from standard care in current clinical practice, 
except that any unnecessary instrumentation should be avoided as associated tissue trauma 
may induce stenosis and the scarring-type tissue response unique to Myhre syndrome. 
Affected individuals who are in heart failure should be under the care of a cardiovascular 
specialist with access to a transplant center. 
Maximize all medical treatment and minimize instrumentation for all cardiac studies and 
therapies. 
Medical treatment of systemic hypertension and pulmonary hypertension (based on underlying 
cause). 
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Respiratory 
Affected individuals have required long-term tracheostomy due to complete and recurrent 
tracheal stenosis following multiple and/or traumatic intubations [McGowan et al 2011, 
Oldenburg et al 2015, Starr et al 2015]. To avoid traumatic intubation, consider using a size-
smaller uncuffed endotracheal tube. Elective tracheal surgery/intubation should be avoided; 
tracheal resection is contraindicated [Oldenburg et al 2015]. 
Symptomatic treatment of restrictive lung disease 
Oxygen supplementation as necessary 
Gastrointestinal 
Minimal instrumentation of the gastrointestinal tract is advised because post-operative 
adhesions can be fatal [Lindor et al 2012]. 
Endoscopy should be approached with caution to avoid airway manipulation which increases 
the risk for tracheal/laryngeal scarring/stenosis [Oldenburg et al 2015]. Noninvasive 3D imaging 
may be preferred. 
Aggressive management of constipation (through dietary means or medication if necessary) is 
indicated. 
Global developmental delay / intellectual disability educational issues. The following 
information represents typical management recommendations for individuals with 
developmental delay / intellectual disability in the United States; standard recommendations 
may vary from country to country. 
Ages 0-3 years. Referral to an early intervention program is recommended for access to 
occupational, physical, speech, and feeding therapy. In the United States, early intervention is a 
federally funded program available in all states. 
Ages 3-5 years. In the United States, developmental preschool through the local public school 
district is recommended. Before placement, an evaluation is made to determine needed services 
and therapies and an individualized education plan (IEP) is developed. 
Ages 5-21 years. In the United States, an IEP based on the individual's level of function should be 
developed by the local public school district. Affected children are permitted to remain in the 
public school district until age 21. 
Discussion about transition plans including financial, vocation/employment, and medical 
arrangements should begin at age 12 years. Developmental pediatricians can provide assistance 
with transition to adulthood. 
All ages. Consultation with a developmental pediatrician is recommended to ensure the 
involvement of appropriate community, state, and educational agencies and to support parents 
in maximizing quality of life. Some issues to consider: 
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Private supportive therapies based on the affected individual’s needs may be considered. 
Specific recommendations regarding type of therapy can be made by a developmental 
pediatrician. 
In the United States: 
Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public 
agency that provides services and support to qualified individuals. Eligibility differs by state but 
is typically determined by diagnosis and/or associated cognitive/adaptive disabilities. 
Families with limited income and resources may also qualify for supplemental security income 
(SSI) for their child with a disability. 
Social/behavioral issues 
Children may qualify for and benefit from interventions used in treatment of autism spectrum 
disorder, including applied behavior analysis (ABA). ABA therapy is individualized therapy 
targeted to each child's behavioral, social, and adaptive strengths and weaknesses and is 
typically performed one on one with a board-certified behavior analyst. 
Consultation with a developmental pediatrician may be helpful in guiding parents through 
appropriate behavioral management strategies or providing prescription medications when 
necessary. 
Individualized behavioral therapy or pharmacologic treatment for anxiety, depression, or other 
psychological manifestations as per current clinical practice is appropriate. 
Hearing 
Hearing loss. Appropriate hearing augmentation (see Deafness and Hereditary Hearing Loss 
Overview) 
Persistent middle ear effusions. Myringotomy tubes as needed 
Craniofacial 
Individuals with orofacial clefting or velopharyngeal insufficiency should be referred to a 
craniofacial clinic with pediatric experience. These individuals benefit most from a 
multidisciplinary approach to care. 
A craniofacial clinic associated with a major pediatric medical center usually includes a surgical 
team (craniofacial surgeon and neurosurgeon), clinical geneticist, ophthalmologist, 
otolaryngologist, pediatrician, radiologist, psychologist, multiple dental specialists, audiologist, 
speech therapist, and social worker. 
Skeletal 
Consider physical therapy to keep joints mobile (no study has been done on efficacy). Note: It is 
not known if passive range of motion exercises help maintain flexibility. 
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A systematic study of growth hormone treatment for short stature has not been done. One 
affected individual has been noted to have anecdotal improvement in growth velocity; however, 
it is unknown if adult height would be affected [Starr et al 2015]. 
Ophthalmology. Routine treatment of strabismus and refractive errors. Note: Complications 
from surgical repair have not been reported. 
Prevention of Secondary Complications 
Limiting tissue trauma appears to be the single most important preventive measure: The 
literature suggests increased risk of proliferative fibrosis following otherwise uncomplicated 
endotracheal intubation and surgical procedures. When possible, alternative noninvasive 
approaches should be pursued during diagnosis and management [Oldenburg et al 2015, Starr 
et al 2015]. 
Extreme care with intubation and use of an endotracheal tube without a cuff (or careful 
monitoring of pressures with a cuff) may help prevent airway stenosis [Oldenburg et al 2015]. 
Minimize abdominal and pelvic procedures as extensive adhesions may develop postoperatively 
[Lindor et al 2012]. 
Hysterectomy should be an option of last resort for treatment of menorrhagia as post-surgical 
fibrosis is highly likely. 
Surveillance 
Cardiovascular 
After normal baseline evaluations of upper- and lower-extremity blood pressure measurements, 
two-dimensional echocardiography with Doppler, and cardiology evaluation 
In asymptomatic individuals with a normal echocardiogram at the time of initial diagnosis, 
repeat echocardiogram every 1-3 years. Note that pericardial effusion and restrictive 
cardiomyopathy may occur at any age and may be clinically asymptomatic [Starr et al 2015, 
Garavelli et al 2016, Lin et al 2016]. 
In individuals with abnormal findings at the time of initial diagnosis, more extensive imaging 
may be indicated given the progressive nature of the disorder (e.g., MRI to evaluate for 
pericardial thickening or effusion). 
Respiratory 
Consider oxygen saturation in children, with monitoring as needed for symptoms suggestive of 
restrictive/obstructive pulmonary disease and annual pulmonary function studies in children 
older than age six years if able to cooperate with test maneuvers. 
Evaluation for upper airway stenosis (e.g., laryngotracheal stenosis) should be considered based 
on symptoms. 
Other 
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Annual ophthalmologic and audiology evaluations 
Monitoring of physical skill development and joint mobility 
Agents/Circumstances to Avoid 
Patients should be aggressively counseled not to smoke. 
Limiting tissue trauma appears to be the single most important preventive concept in this 
disorder to communicate to all health care providers involved in their care (see Prevention of 
Secondary Findings). 
Evaluation of Relatives at Risk 
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling 
purposes. 
Therapies Under Investigation 
Search ClinicalTrials.gov in the US and www.ClinicalTrialsRegister.eu in Europe for access to 
information on clinical studies for a wide range of diseases and conditions. Note: There may not 
be clinical trials for this disorder. 
Genetic Counseling 
Genetic counseling is the process of providing individuals and families with information on the 
nature, inheritance, and implications of genetic disorders to help them make informed medical 
and personal decisions. The following section deals with genetic risk assessment and the use of 
family history and genetic testing to clarify genetic status for family members. This section is not 
meant to address all personal, cultural, or ethical issues that individuals may face or to 
substitute for consultation with a genetics professional. —ED. 
Mode of Inheritance 
Myhre syndrome is inherited in an autosomal dominant manner. 
Risk to Family Members 
Parents of a proband 
All probands with Myhre syndrome reported to date have the disorder as a result of a de novo 
SMAD4 pathogenic variant (see Bassett et al [2016]; Lin et al [2016] and references therein). 
Recommendations for the evaluation of parents of a proband with an apparent de novo 
pathogenic variant include molecular genetic testing. 
Sibs of a proband. If the SMAD4 pathogenic variant found in the proband cannot be detected in 
the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that 
of the general population (though still <1%) because of the theoretic possibility of parental 
germline mosaicism. 
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Offspring of a proband. To date, individuals with Myhre syndrome are not known to reproduce 
and fertility has not been assessed. 
Other family members. The risk to other family members is presumed to be low given that all 
probands with Myhre syndrome reported to date have the disorder as a result of a de novo 
SMAD4 pathogenic variant (i.e., no familial cases of Myhre syndrome have been reported). 
Related Genetic Counseling Issues 
Family planning 
The optimal time for determination of genetic risk and discussion of the availability of prenatal 
testing is before pregnancy. 
It is appropriate to offer genetic counseling (including discussion of potential risks to offspring 
and reproductive options) to parents of affected individuals. 
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible 
future use. Because it is likely that testing methodology and our understanding of genes, allelic 
variants, and diseases will improve in the future, consideration should be given to banking DNA 
of affected individuals. 
Prenatal Testing and Preimplantation Genetic Diagnosis 
Once the SMAD4 pathogenic variant has been identified in an affected family member, prenatal 
testing for a pregnancy at theoretic increased risk and preimplantation genetic diagnosis for 
Myhre syndrome are possible. 
Resources 
GeneReviews staff has selected the following disease-specific and/or umbrella support 
organizations and/or registries for the benefit of individuals with this disorder and their families. 
GeneReviews is not responsible for the information provided by other organizations. For 
information on selection criteria, click here. 
National Library of Medicine Genetics Home Reference 
Myhre syndrome 
Alexander Graham Bell Association for the Deaf and Hard of Hearing 
3417 Volta Place Northwest 
Washington DC 20007 
Phone: 866-337-5220 (toll-free); 202-337-5220; 202-337-5221 (TTY) 
Fax: 202-337-8314 
Email: info@agbell.org 
 
Listening and Spoken Language Knowledge Center 
American Society for Deaf Children (ASDC) 
800 Florida Avenue Northeast 
Suite 2047 
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Washington DC 20002-3695 
Phone: 800-942-2732 (Toll-free Parent Hotline); 866-895-4206 (toll free voice/TTY) 
Fax: 410-795-0965 
Email: info@deafchildren.org; asdc@deafchildren.org 
www.deafchildren.org 
 
National Association of the Deaf (NAD) 
8630 Fenton Street 
Suite 820 
Silver Spring MD 20910 
Phone: 301-587-1788; 301-587-1789 (TTY) 
Fax: 301-587-1791 
Email: nad.info@nad.org 
www.nad.org 
 
Molecular Genetics 
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the 
GeneReview: tables may contain more recent information. —ED. 
Table A. 
Myhre Syndrome: Genes and Databases 
Gene Chromosome 
Locus 
Protein Locus-Specific 
Databases 
HGMD ClinVar 
SMAD4 18q21.2 Mothers against 
decapentaplegic homolog 
4  
SMAD4 
Database 
SMAD4 
database 
SMAD4 SMAD4 
Data are compiled from the following standard 
references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a 
description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here. 
Table B. 
OMIM Entries for Myhre Syndrome (View All in OMIM) 
139210 MYHRE SYNDROME; MYHRS 
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600993 MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 4; 
SMAD4 
 
Molecular Genetic Pathogenesis 
Myhre syndrome is caused by a heterozygous SMAD4 gain-of-function pathogenic variant that 
confers stability on the abnormal SMAD4 protein due to an apparent decrease in 
monoubiquitination. This disrupts TGFβ signaling, thus altering expression of downstream target 
genes encoding TGFβ and bone morphogenic proteins (BMP), resulting in abnormal 
development of the axial and appendicular skeleton, cardiac muscle, and central nervous system 
[Caputo et al 2012, Le Goff et al 2014]. 
In contrast, heterozygosity for a loss-of-function SMAD4 pathogenic variant has been well 
established as the cause of a spectrum of acquired cardiac diseases, including cardiac fibrosis 
and hypertrophy, aortopathies, atherogenesis, and pulmonary artery hypertension. 
Gene structure. The coding exons 2-12 of SMAD4 constitute a 552-residue protein composed of 
two domains. Exon 1 is noncoding. 
Pathogenic variants. The four pathogenic variants reported to date are missense variants that 
are restricted to residues 496 and 500 (Table 3). No inactivating deletions or duplications have 
been reported in individuals with Myhre syndrome. 
Since 2011, when heterozygosity for a SMAD4 pathogenic variant was found to be causative, 55 
affected individuals with a molecularly confirmed diagnosis of Myhre syndrome have been 
reported. Lin et al [2016] reported four affected individuals and summarized findings in 50 
previously reported individuals [Le Goff et al 2011, Al Ageeli et al 2012, Asakura et al 2012, 
Caputo et al 2012, Lindor et al 2012, Picco et al 2013, Ishibashi et al 2014, Kenis et al 2014, 
Michot et al 2014, Hawkes & Kini 2015, Oldenburg et al 2015, Starr et al 2015]. Subsequently 
Bassett et al [2016] reported one additional affected individual. 
Table 3.  
SMAD4 Pathogenic Variants Discussed in This GeneReview 
DNA Nucleotide Change Predicted Protein Change Reference Sequences 
c.1486C>T p.Arg496Cys 
NM_005359.5 
NP_005350.1 
c.1498A>G p.Ile500Val 
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DNA Nucleotide Change Predicted Protein Change Reference Sequences 
c.1499T>C p.Ile500Thr 
c.1500A>G p.Ile500Met 
Note on variant classification: Variants listed in the table have been provided by the 
authors. GeneReviews staff have not independently verified the classification of variants. 
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human 
Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of 
nomenclature 
 
Note on variant classification: Variants listed in the table have been provided by the authors. 
GeneReviews staff have not independently verified the classification of variants. 
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human 
Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of 
nomenclature. 
Normal gene product. The three functional classes of SMADs are: 
SMAD4 that encodes a SMAD protein known as the co-mediator of the SMADs; 
SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8 that are the receptor-regulated SMADs (or R-
SMADs); 
SMAD6 and SMAD7 that are inhibitory SMADs. 
SMAD4 (mothers against decapentaplegic homolog 4) forms heterodimers with the receptor-
regulated SMADs, which are translocated to the nucleus of the cell, which then (via an unclear 
mechanism) regulates the expression of TGBβ and BMP pathway genes. 
The 11 coding exons of SMAD4 constitute a 552-residue protein composed of two domains [Shi 
& Massague 2003, Le Goff et al 2011, Caputo et al 2012]: 
Mad homology 1 (MH1), which contributes to DNA binding 
Mad homology 2 (MH2), which activates transcription 
Abnormal gene product. Codons 496 and 500 are in the Mad homology 2 domain; pathogenic 
variants in these codons confer a gain of function to the protein. The work of Le Goff et al [2011] 
indicated that defective transcriptional regulation during development plays a significant role in 
the disorder. 
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Cancer and benign tumors. Although germline SMAD4 loss-of-function (inactivating) pathogenic 
variants predispose to hamartomatous polyps in the gastrointestinal track (see Juvenile 
Polyposis Syndrome), the gain-of-function pathogenic variants associated with Myhre syndrome 
show no such associations (see Clinical Description, Neoplasia). 
Note that somatic inactivation of SMAD4, a gastrointestinal malignancy-specific tumor 
suppressor gene, is found in one third of colorectal cancer specimens and half of pancreatic 
tumors. See Chen et al [2014] and references therein. 
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ABSTRACT 
PIGQ (OMIM *605754) encodes phosphatidylinositol-glycan biosynthesis class Q 
(PIGQ) and is required for proper function of the N-acetylglucosomine (GlcNAc) 
transferase complex in a similar manner to the more established PIGA, PIGC, and PIGH.  
There are two previous patients reported with homozygous and apparently deleterious 
PIGQ mutations.  Here we provide the first detailed clinical report of a patient with 
heterozygous deleterious mutations associated with a glycosylphosphatidylinositol-
anchored protein (GPI-AP) biosynthesis deficiency.  Our patient died at 10 months of age.  
The rare skeletal findings in this disorder expand the differential diagnosis of long bone 
radiolucent lesions and sphenoid wing dysplasia. This clinical report describes a new and 
rare disorder — PIGQ GPI-AP biosynthesis deficiency syndrome.        
Keywords: inherited glycosylphosphatidylinositol-anchored protein (GPI-AP) deficiency, 
PIGQ, developmental delay, bone lesion, sphenoid wing dysplasia 
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INTRODUCTION 
The inherited congenital disorders of glycosylation include a subset of disorders 
that include genes involved in GPI-AP biosynthesis and attachment. When damaged, 
these phosphatidylinositol-glycan (PIG) genes lead to a variety of clinical features 
including global developmental delay, multiple congenital anomalies, hypotonia, and 
epileptic seizures.  Collectively, these associated syndromes are inherited GPI-AP 
biosynthesis deficiencies, with specificity derived from the precise gene involved in each 
condition. PIGQ (OMIM *605754) encodes phosphatidylinositol-glycan biosynthesis class 
Q (PIGQ) and is required for proper function of the GlcNAc transferase complex in a similar 
manner to PIGA, PIGC, and PIGH.  PIGQ was shown to be critical for the GPI biosynthesis 
in in vitro studies as early as 2001 (Tiede et al., 2001).  There are two prior reports of 
patients with deleterious PIGQ mutations.  Both reports were complicated by 
consanguinity with multiple regions of homozygosity, limited clinical information, and no 
photographs or radiographs.  (Alazami et al., 2015; Martin et al., 2014).  
Herein, we describe a patient with a multisystem disorder and compound 
heterozygous deleterious changes in PIGQ.  His clinical features included coarse, 
dysmorphic facial features, pectus excavatum, marked abdominal laxity, and deep plantar 
creases. He had multisystem involvement with epileptic seizure disorder, ophthalmic 
anomalies, cyclical vomiting, hepatic nodule, bilateral cystic renal dysplasia, prune-belly-
like abdomen, and bilateral inguinal hernias.  Skeletal anomalies included sphenoid wing 
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dysplasia, progressive scoliosis and metaphyseal radiolucent lesions in the femora and 
tibiae. 
CLINICAL REPORT 
The patient was the third child of nonconsanguineous parents. He was born at 39 
weeks gestation at a weight of 3.6 kg via repeat C-section.  Pregnancy was complicated 
by severe polyhydramnios requiring multiple amniocentesis fluid reduction procedures.  
Prenatal microarray was normal.  He was discharged to home at 4 days of age without 
any recorded medical concerns.  Parents noted he had some difficulty feeding and 
trembling episodes in the newborn period.  At 2 months of age there were times where 
he would gasp and flail his arms.  An EEG done at that time was unremarkable, but the 
episodes in question were not captured during the recording.  Neurologic examination, 
including deep tendon reflexes specifically, was noted by his neurologist to be normal for 
age.   
By 4 months of age (6.3 kg, 15th centile, length:  61 cm 5th centile, head:  43 cm 
85th centile), lack of head control, episodes of gasping with lip quivering, central apnea 
diagnosed via sleep study, and poor feeding prompted further imaging and surveillance.  
At that time, he could independently raise his head and was suspected to have vision loss 
due to lack of fixation or tracking.  Facial and physical characteristics included coarse facial 
features, hooded upper eyelids with mild ptosis, telecanthus, fleshy and uplifted ear 
lobes, thick alae nasi with broad nasal tip, and anteverted nares. He had full, almost 
pendulous, cheeks, a long and smooth philtrum, thin vermilion of the upper lip, down-
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turned corners of the mouth, and mild micrognathia.  He also had pectus excavatum, 
diastasis recti, bilateral inguinal herniae, abdominal wall laxity, soft and sagging skin, and 
deep plantar creases (Fig. 1).  He began to have frequent episodes of vomiting and 
decreased oral intake.  His neurologist noted at 5 months of age that his truncal hypotonia 
had progressed and his deep tendon reflexes were reduced to 1+.   
 Ophthalmic involvement included vertical nystagmus, bilateral hyperopia with 
astigmatism, cortical visual impairment, delayed visual maturation, punctate keratitis of 
both eyes, and alacrima with decrease of corneal sensation.  Cardiovascular system 
involvement was only significant for a patent foramen ovale identified at 17 weeks of age.  
Assessment of the gastrointestinal/hepatic systems revealed heterogeneous liver 
echotexture, right hepatic-lobe lesion (8 x 5 x 6 mm), and normal liver function studies. A 
cyclic-vomiting disorder developed that required multiple hospital admissions for 
intravenous fluids. The right kidney (Fig. 2) was small with increased cortical echogenicity 
and diminished cortical medullary differentiation.  Both kidneys had multiple small renal 
cortical cysts and a triangular focus of hyperechogenicity near the lower pole papilla with 
twinkle artifact representing calcification or calculi.  There was grade three vesicoureteral 
reflex on the right and grade one on the left.  Renal function was otherwise normal until 
just prior to death.   
At age 7-months the patient had persistent clusters of myoclonic jerks with 
extremity stiffening, lip quivering, back-arching with upper extremities appearing floppy, 
and decreased responsiveness. Repeat sleep/awake EEG done at this time showed 
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frequent epileptiform discharges arising from the right temporal, central and bilateral 
occipital areas. Keppra was initiated with a goal of titration to 20mg/kg/day. 
Unfortunately, the child was noted to have refractory irritability interfering with sleep and 
oral intake.  He was admitted at this time for epileptic seizure and was given lorazepam. 
He was loaded with fosphenytoin (20PE/kg) resulting in resolution. The episode lasted a 
total duration of approximately 33 minutes. He returned to previous baseline after 
overnight admission. An EEG done the next day showed high amplitude diffuse 
background slowing but no focal, lateralizing, or epileptiform patterns.  Keppra was not 
resumed and the child was started on phenobarbital at 3mg/kg/day instead.  At 9 months 
of age, a follow-up EEG showed multifocal epileptiform activity in the form of high 
amplitude spike and slow wave complexes in the right occipital region, as well as spikes 
and polyspikes with associated slow potentials in bilateral temporal and posterior 
temporal regions. The infant developed an erratic sleeping pattern with an average of 
only 4 hours of sleep per day. He also acquired cyclical vomiting with intractable 
trembling, followed by crying episodes. Phenobarbital was therefore increased to 
approximately 5mg/kg/day. Clonidine was also trialed for continued episodes of emesis 
with minor improvement.  
 At 10 months of age (weight: 7.8 kg 5th centile, length:  69 cm < 2%, and head 
measured 45 cm 50th centile) he presented with increased work of breathing and 
tachycardia. There were sick contacts in the family. He was found to have leukocytosis 
and severe respiratory acidosis and was therefore transferred to the pediatric intensive 
care unit for further care. He was febrile during the hospital stay but all cultures remained 
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negative with negative respiratory viral panel.  Over the next 3 days his respiratory status 
stabilized and he was therefore transferred to the pediatric ward. He was trialed on 
gabapentin along with increase in clonidine for worsening episodes of vomiting during 
this admission.  The fourth day after admission he was noted to have an epileptic seizure 
activity in the setting of high fever.  Multiple doses of phenobarbital and fosphenytoin 
eventually led to resolution, but this was followed by respiratory failure, hypotension, and 
pulseless electrical activity that did not respond to resuscitative efforts resulting in 
demise. Parents did not want an autopsy to be performed. 
MRI of the brain at 5 months of age and CT of the brain at 10 months of age, done 
for the significant change in mental status, revealed plagiocephaly with ventriculomegaly 
(left>right) (Fig. 3).  The skeletal findings (Fig. 4) included a large anterior fontanelle, 
sphenoid wing dysplasia and an intrasutural bone of the coronal suture.   Thoracolumbar 
scoliosis and pectus excavatum were apparent by 6 months of age and progressed until 
death.  Transient radiolucent lesions of the long bones were seen on his first osseous 
survey at 3 months of age.  There was resolution of the proximal tibial lesions, 
enlargement of distal right femoral metaphysis lesion, and a new cortical lucency in the 
right femoral neck on subsequent radiographs at 10 months of age.  Alkaline phosphatase 
levels were elevated throughout his life at 480-836 U/L (reference: 150 - 440 U/L).  
Attempts to obtain a sample for flow cytometry were unsuccessful.      
Whole exome sequencing performed at age 4-months revealed a maternal 
frameshift mutation c.968_969delTG (p.L323Pfs*119) resulting in premature protein 
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truncation and a paternal origin in-frame deletion c.1199_1201delACT (p.Y400del) at 
position 400, which is completely conserved in vertebrates (0.02% frequency in ExAC 
database), in PIGQ.  The mutations of this patient were previously reported as predicted 
to be highly deleterious by the laboratory that did the exome sequencing in an article 
demonstrating effectiveness of identifying candidate genes of disease from exome 
sequencing (Farwell Hagman et al., 2018). 
DISCUSSION 
Patients with the variety of PIG GPI-AP disorders share some resemblance to our 
patient. Global developmental delays, epileptic seizures, and dysmorphic features affect 
nearly all patients, and ophthalmic, renal, and skeletal anomalies (Bellai-Dussault, 
Nguyen, Baratang, Jimenez-Cruz, & Campeau, 2018; Nguyen et al., 2018) are common.  
Individuals with PIGT- and PIGA- associated GPI-AP deficiency share some of the rarer 
features, including anteverted nares, uplifted fleshy ear lobes, proximally placed great 
toes, and deep plantar creases (Lam et al., 2015; Tarailo-Graovac et al., 2015; Yang et al., 
2018). 
The bone lesions reported here are the first such findings reported in patients with 
GPI-AP deficiency disorders.  PIGQ-associated (GPI-AP) deficiency expands the short 
differential diagnosis for the association of ill-defined radiolucent long bone lesions and 
sphenoid wing dysplasia.  Our patient had normal sequencing with deletion/duplication 
analysis of NF1; completed in response to the sphenoid wing dysplasia.  Infantile 
myofibromatosis and congenital syphilis were also on the differential diagnosis, but 
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neither fit his clinical findings.   
PIGQ is involved in the initial phase of GPI-anchor biosynthesis.  Because GPI-
anchors are required to attach proteins to the cell surface during embryogenesis, 
structural development is compromised across most body systems.  We postulate that 
our patient with disrupted PIGQ function could not appropriately utilize bone minerals 
including phosphorous, calcium, and magnesium because of the lack of proper 
attachment of alkaline phosphatase to the osteoblast.  This may explain the migrating 
radiolucent bone lesions that our patient exhibited on osseous surveys.  
To our knowledge, this is the first clinical report of a patient with compound 
heterozygous mutations in PIGQ and he is the third patient with suspected PIGQ-related 
disorder (Alazami et al., 2015; Martin et al., 2014). The patient described by Martin et al 
(2014) had Ohtahara syndrome with homozygous PIGQ mutations discovered through 
whole genome sequencing.  The mutation was in a conserved splice acceptor site of exon 
3 (homozygous c.690-2A>G), which induced exon-skipping resulting in an in-frame 
deletion of 44 amino acids. This patient, born to consanguineous parents, had dysmorphic 
craniofacial features, hypotonia, vision problems, gastrostomy-tube dependency, and 
profound developmental delay. The Martin group further showed the patient's variant 
was pathogenic when, in vitro, they could not restore expression of GPI-anchored 
proteins to wild type levels in PIGQ-deficient Chinese hamster ovary cells, suggesting a 
loss-of-function. This patient died at 2 years of age during a severe respiratory illness. One 
additional patient, also born to consanguineous parents, was noted in a supplementary 
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table by Alazami et al., in 2015 with homozygous c.619C>Tp.R207* mutations proposed 
to be the etiology of epilepsy, optic atrophy, and developmental delay.  
Taken together, the three patients support evidence for a new syndrome — PIGQ-
related GPI-AP biosynthesis deficiency syndrome.  Phenotypic variability is expected to 
increase with ongoing reports of these patients.  With improved sequencing diagnostic 
tools now available and more rapid processing, PIG GPI-AP biosynthesis deficiencies will 
be identified earlier.  Treatments based on improving the underlying process may 
improve the quality of life for these patients.   
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FIGURE LEGENDS 
 
 
 
CHAPTER 3., FIGURE 1.  Newborn through 9 months of age.  Coarse facial features, 
hooded upper eyelids, telecanthus, mild ptosis, fleshy and uplifted ear lobes, thick ala 
nasi with broad nasal tip and anteverted nares, long and smooth philtrum, thin 
vermillion of the upper lip, down-turned corners of the mouth, mild micrognathia 
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(A,B,C,D,E,F,G).  Abdominal wall laxity (C, D), sagging skin (A,D,E,F), diastasis recti (D), 
pectus excavatum (H), and deep plantar creases (I).   
 
CHAPTER 3., FIGURE 2. Right kidney was small with increased cortical echogenicity and 
diminished cortical medullary differentiation, multiple small cortical cysts.   
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CHAPTER 3., FIGURE 3.  MRI of the brain at 5 months (A) and CT of the brain at 10 
months (B) revealed left greater than right ventriculomegaly and worsening cranial 
plagiocephaly. 
 
 
 
CHAPTER 3., FIGURE 4. Skeletal findings.  Intrasutural bone (A), sphenoid wing dysplasia 
at 3 months (B) and 10 months (C). Chest and abdomen radiographs at 3 (D) and 10 (E) 
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months of age.  Note worsening of thoracolumbar scoliosis.  (F) 3 months. There are Ill-
defined radiolucent areas in the metaphyses of the right femur and tibia. (G) 10 months. 
Compared to the films obtained at age 3 months (F) the femoral lesion has expanded, 
the tibial lesion has disappeared.   
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